Human SDC2 Gene Methylation Detection Kit
Brochure Download
Fill out the form to download
Human SDC2 Gene Methylation Detection Kit is a PCR-based in vitro diagnostic test designed to qualitatively detect methylation status of the SDC2 gene promoter region in human stool specimens. It provides clinicians with auxiliary reference for the adjunctive diagnosis of colorectal cancer and precancerous lesions including adenomas and polyps, and supports clinical decision-making for colonoscopy referral.
Product Features
- High Sensitivity: Reliably detect ≥1% methylated DNAagainst wild-type DNA background; detection limit down to 2 ng/μL genomic DNA.
- High Specificity: Based on methylation-specific TaqMan probe PCRtechnology, specifically recognizes methylated SDC2 sequences with no cross-interference from other common methylated markers or non-human DNA.
- High Accuracy: Integrated internal control (ACTB)and UNG contamination control system; closed-tube operation minimizes false positives and false negatives.
- Quick & Easy: Simplified workflow with minimal operation steps; results can be completed in approximately 90 minutes.
- Non-invasive & Convenient: Stool sampling with no dietary restriction or bowel preparation; samples storable at room temperature for transport.
| Cat.No. | Product Name | Technology | Specification | Supply Format |
| YZYMT-044 | Human SDC2 Gene Methylation Detection Kit | PCR-Fluorescence Method | 12 tests/kit | RUO |
Clinical Significance
SDC2 (Syndecan-2) is a key member of heparan sulfate proteoglycans that regulates cell signaling and suppresses tumor metastasis. Hypermethylation of the SDC2 promoter is an early and specific molecular event in colorectal tumorigenesis, leading to silencing of the tumor-suppressor function and driving malignant transformation.
This epigenetic alteration can be detected in early-stage colorectal cancer, adenomas and polyps. Shedding tumor cells release methylated DNA into stool, enabling non-invasive detection. SDC2 methylation is a well-recognized biomarker for early screening of colorectal neoplasms and is recommended in multiple expert consensuses and guidelines for colorectal cancer early detection.
SDC2 methylation testing identifies early-stage and precancerous lesions with high performance, enabling timely intervention and significantly improving patient prognosis.
References
Oh T J, et al. Clinical Epigenetics, 2017; Niu F, et al. Cancer Epidemiol Biomarkers Prev, 2017.